Principal Financial Group Inc. Sells 25,944 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Principal Financial Group Inc. trimmed its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 49.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 26,907 shares of the company’s stock after selling 25,944 shares during the quarter. Principal Financial Group Inc.’s holdings in Kiniksa Pharmaceuticals were worth $532,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Wellington Management Group LLP purchased a new position in shares of Kiniksa Pharmaceuticals in the 3rd quarter valued at approximately $1,192,000. JPMorgan Chase & Co. bought a new position in Kiniksa Pharmaceuticals in the third quarter worth $4,997,000. Parkman Healthcare Partners LLC lifted its position in Kiniksa Pharmaceuticals by 16.7% during the third quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company’s stock valued at $18,874,000 after buying an additional 108,102 shares during the period. Segall Bryant & Hamill LLC bought a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter valued at $675,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Kiniksa Pharmaceuticals in the 4th quarter worth about $355,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Insider Transactions at Kiniksa Pharmaceuticals

In other news, COO Eben Tessari sold 14,000 shares of the business’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $18.24, for a total value of $255,360.00. Following the completion of the transaction, the chief operating officer now owns 88,975 shares in the company, valued at $1,622,904. The trade was a 13.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 54.57% of the company’s stock.

Analyst Ratings Changes

Separately, Wedbush reissued an “outperform” rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals has a consensus rating of “Buy” and an average price target of $36.60.

Kiniksa Pharmaceuticals Stock Down 0.6 %

KNSA stock opened at $21.27 on Friday. The business has a 50 day moving average of $19.73 and a 200 day moving average of $22.40. The firm has a market cap of $1.54 billion, a PE ratio of -151.92 and a beta of 0.48. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $16.56 and a twelve month high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The company had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals’s revenue was up 46.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.35 earnings per share. On average, research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.